Key Points {#FPar1}
==========

The Janus kinase/signal transduction and activator of transcription pathway transduces downstream of multiple cytokines critical to the pathogenesis of immune-mediated disease.Janus kinase inhibitors are effective treatments for rheumatoid arthritis and are under investigation for many other immune-mediated diseases including psoriasis, systemic lupus erythematosus, inflammatory bowel disease, and rare autoinflammatory diseases with a type 1 interferon signature.Second-generation Janus kinase inhibitors are more selective than currently approved drugs and are being studied for therapeutic efficacy and side-effect profile.

Introduction {#Sec1}
============

Cytokines are the soluble messengers that immune cells use to communicate, ultimately modulating protective responses against pathogens \[[@CR1]\]. Yet, cytokines may also drive the dysregulated immune responses that characterize autoimmune diseases such as rheumatoid arthritis (RA). Inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 maintain and aggravate inflammation in RA: they induce activation of leukocytes, endothelial cells, and fibroblasts like synoviocytes, promote differentiation of pathogenic immune cells, and promote synthesis of metalloproteinases that erode the joint \[[@CR2]\]. The development over the past decade and a half of agents targeting cytokines or their receptors, denoted 'biologics', represents a landmark advancement in the treatment of autoimmune and inflammatory diseases. These agents include monoclonal antibodies and recombinant proteins that target cytokines or cytokine receptors, such as TNF-α, IL-6, and its receptor, IL-1, and others. However, despite the therapeutic success of biologics, it has become evident that targeting a single cytokine does not completely abrogate the pathology of rheumatologic disease for all patients. In addition, many of these agents lose efficacy over time owing to immunogenicity \[[@CR3]\] and the intravenous or subcutaneous administration of these agents is an obstacle for some patients.

Over the past 20 years, our knowledge of the intracellular pathways downstream of cytokine receptors has greatly increased, and the inhibition of intracellular enzymes such as receptor-associated kinases represents a novel way to simultaneously inhibit multiple cytokines. Small orally available molecules can be passively transported through the cellular membrane and block the intracellular activity of their targets \[[@CR3]--[@CR6]\].

The type I/II cytokine receptor family is used by several cytokines implicated in the pathogenesis of rheumatologic disease \[[@CR1], [@CR5]\]. This family of cytokine receptors employs the Janus kinase-signal transduction and activation of transcription (JAK--STAT) pathway to effect signal transduction \[[@CR7]\]. Upon binding of a type I/II cytokine to its cognate receptor, receptor-associated JAKs are activated and phosphorylate STATs, transcription factors critical for the activation of cytokine-specific genetic programs. Given the major role played by JAKs and STATs in the pathogenesis of autoimmunity \[[@CR8], [@CR9]\], it is perhaps no surprise that small molecules targeted against JAKs, or Jakinibs, represent an emerging treatment for autoimmune and inflammatory disease. In this review, we have described the JAK--STAT pathway and its role in human diseases, and then we have discussed the efficacy and safety of individual Jakinibs in different diseases. Electronic databases of EMBASE, PubMed, and SCOPUS were searched to identify all reports published in the English language that described 'Janus kinase', 'JAK/STAT pathway', 'role of JAK/STAT pathway in human diseases', and 'JAK inhibitors'. We also searched relevant conferences for abstracts describing Jakinibs or the JAK--STAT pathway, searched Clinicaltrials.gov for individual Jakinibs, and reviewed press releases from Pfizer, Lilly, Galapagos, Incyte, and Abbvie.

Structure of JAKs and STATs, and Implications for Targeted Therapy {#Sec2}
==================================================================

JAKs belong to the family of tyrosine kinases (TYKs). The basic structure of all JAKs consists of four structural domains composed of seven homologous regions \[JH1--7\] (Fig. [1](#Fig1){ref-type="fig"}). JH1 and JH2 denote the kinase and pseudokinase domains: the name Janus is an allusion to the double-faced Roman god of gates and doors owing to the presence of these two kinase domains. JH1 is the active catalytic phosphotransferase domain and the target of the Jakinibs developed so far, which compete with adenosine triphosphate at the catalytic site. Because the JH1 domains of the four JAKs exhibit a high degree of homology not only within the JAKs but also with other TYKs, development of a selective Jakinib has been challenging.Fig. 1Structure of Janus kinase (JAK) and signal transduction and activation of transcription (STAT) molecules. **a** Linear structure of JAK molecule showing the different domains. JAKs have four functional domains: the kinase, pseudokinase, Four-point-one protein, Ezrin, Radixin and Moesin domain (FERM), and Src Homology 2 (SH2) domains. The kinase domain is the site of catalytic activity and inhibition by JAK inhibitors (Jakinibs). The FERM and pseudokinase domain interact with the kinase domain and primarily have regulatory functions. An alternative nomenclature for the domains based on their amino acid sequence classifies them as seven Janus homology (JH) domains. **b** Simplified three-dimensional image of JAK. The crystal structure of the FERM and SH2 domain was recently described and may contribute to receptor recognition. JH1 and JH2 are the kinase and pseudokinase domains respectively. **c** Linear structure of STAT molecule showing different domains. STAT proteins contain an amino terminal, a coiled coil, a DNA-binding domain (DBD), a linker, an SH2, and a transcriptional activation domain. The TAD domain is located at the C terminus and undergoes serine phosphorylation to recruit additional transcriptional activators. **d** Simplified three-dimensional image of STAT. Activated STAT dimers form a nutcracker-like structure as shown in this figure. The hinge of the nutcracker is formed by highly conserved SH2 domain and is commonly the target of STAT inhibitors. The linker region and DBD surround centrally located chromatin like the jaws of the nutcracker

The pseudokinase domain (JH2) was thought to have a regulatory function rather than a catalytic activity \[[@CR5]\]: JH2 suppresses ligand-independent kinase activity through direct interactions with JH1 but is also required for ligand-induced JAK activation \[[@CR10]\]. Recent work, however, has demonstrated that in JAK2, the JH2 has low-level catalytic activity \[[@CR11], [@CR12]\]. JH3 and JH4 are primarily involved in stabilizing the structural conformation of the enzyme whereas the JH5, JH6, and JH7/Four-point-one protein, Ezrin, Radixin, and Moesin domain (FERM) are critical for the association of the JAKs with their cognate receptors \[[@CR13]\]. Notably, recent mapping of the FERM domains of receptor-bound JAK1 and TYK2 revealed striking differences in the structure that confers binding specificity, which might be exploited for the generation of selective inhibitors \[[@CR5], [@CR14]--[@CR16]\].

The STAT transcription factors transmit type I/II cytokine signals downstream of the JAKs. STAT proteins contain an amino terminal, a coiled coil, a DNA-binding domain (DBD), a linker, a Src-homology2 (SH2), and a transcriptional activation domain (TAD) \[[@CR17]\] (Fig. [1](#Fig1){ref-type="fig"}). Inactive cytoplasmic STATs exist primarily as monomers or preformed dimers \[[@CR18]\]; upon activation, STAT dimers form a nutcracker-like structure. The highly conserved SH2 domain forms the hinge of this structure and is the target of most patented STAT inhibitors \[[@CR19]\]. The linker region and DBD surround the centrally located chromatin like the jaws of the nutcracker, whereas the TAD is located at the C terminus and undergoes serine phosphorylation to recruit additional transcriptional activators and enhance transcriptional activity. These areas display the lowest sequence conservation \[[@CR20]\]. Given the involvement of STATs in signaling events downstream of cytokine receptors as well as growth factors, STATs have long been considered as potential therapeutic targets for cancer and autoimmune disease \[[@CR19]\]. Therefore, low-sequence conservation areas could represent a target for inhibitors, such as DNA-binding decoy oligonucleotides, with increased selectivity \[[@CR21]\].

JAK--STAT Signaling {#Sec3}
===================

The JAK--STAT pathway has been used for over 500 million years as a means of intracellular signal transduction in response to cytokines and growth hormones, evolving before the divergence of protostomes from deuterostomes \[[@CR22]\]. The canonical signaling cascade is initiated when type I/II cytokines bind to their cognate receptors (Fig. [2](#Fig2){ref-type="fig"}). Type I/II receptors are composed of distinct chains, which oligomerize upon binding of the cytokine. Oligomerization causes separation of the intracellular subunits of the cytokine receptor, which moves the receptor-associated JAKs apart from each other, relieving constitutive inhibition and resulting in their activation \[[@CR1], [@CR7], [@CR23], [@CR24]\]. The JAKs phosphorylate themselves and the intracellular portion of the receptors, which serve as docking sites for STAT transcription factors \[[@CR25]\], which, in turn, are also phosphorylated. When phosphorylated by JAKs, inactive cytosolic STAT monomers undergo a conformational change that allows for the formation of active homodimers, heterodimers, or tetramers. The active STATs can then translocate into the nucleus where they act as transcription factors to regulate gene expression \[[@CR1], [@CR26], [@CR27]\].Fig. 2Cytokine signaling through the Janus kinase-signal transduction and activation of transcription (JAK--STAT) pathway. Binding of cytokine to the receptor leads to activation and phosphorylation of JAK and phosphorylation of the receptor. This in turn leads to phosphorylation and dimerization of STAT. Activated STAT dimer migrates to the nucleus and binds to specific DNA-binding sites regulating gene transcription. This culminates in alteration of cellular function

There are four JAK namely, JAK1, JAK2, JAK3, and TYK2 \[[@CR5]\]. Different JAK-dependent cytokine receptors signal through different JAKs. Each receptor is composed of multiple subunits, and each subunit associates with a JAK (Fig. [3](#Fig3){ref-type="fig"}). Some receptor chains associate selectively with a specific JAK, whereas some are less selective. Thus, the extent to which a particular type I/II cytokine depends on a specific JAK to transduce signals is determined by the subunits of that cytokine's receptor (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). For example, the common γ-chain (γc), used by IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, associates exclusively with JAK3 and is the only receptor subunit that uses JAK3 \[[@CR28]\]. Other receptor chains are able to associate with more than one JAK isoform: for instance, the gp130 subunit can use JAK1, JAK2, and possibly TYK2 \[[@CR16]\]. A further layer of specificity is conferred by the pairing of specific receptor chains with each other: thus, the γc pairs exclusively with JAK1-associated receptor subunits. Most type I/II cytokine receptors signal through multiple JAKs as a result of this pairing of distinct JAK-associated subunits. JAK2-associated growth factor and hormone-like cytokine receptors are the exception and their subunits have the unique property of self-pairing \[[@CR5]\].Fig. 3Physiological significance of Janus kinase (JAK) pathways and mechanism of action of new-generation, small-molecule JAK inhibitors (Jakinibs). Binding of various type I/II cytokines to specific receptor subunits leads to activation of specific JAK pathways. For example, γ-common chain (γc) associates only with JAK3 and mediates signaling of interleukin (IL)-2, IL-4, IL-7, IL-15, and IL-21. However, JAK1 has a broader role in cytokine signaling. Newer generation Jakinibs block specific JAK molecules compared with the first-generation Jakinibs that are non-selective. Thereby, the new-generation Jakinibs should have fewer side effects while maintaining similar efficacy as first-generation Jakinibs. However, some degree of off-target side effects such as cytopenias are seen even with selective Jakinibs such as decernotinib and ABT494. *EPO* erythropoietin, *GH* growth hormone, *GM-CSF* granulocyte macrophage-colony stimulating factor, *IFN* interferon, *TH* T-helper, *TPO* thrombopoietin, *TYK* tyrosine kinase Table 1Type I cytokine receptors, ligands, and associated Janus kinase (JAK) and signal transduction and activator of transcription (STAT) moleculesCommon receptor chainLigand/cytokineAssociated JAKAssociated STATγ ChainIL-2, IL-7, IL-9, IL-15, IL-21JAK1, JAK3STAT5, STAT3IL-4JAK1, JAK3STAT6Shares IL-4Rα subunitIL-13JAK1, JAK2, JAK3, TYK2STAT6β~C~IL-3, IL-5JAK2STAT3, STAT5, STAT6GM-CSFJAK2STAT3, STAT5gp130IL-6, IL-11JAK1, JAK2, TYK2STAT1, STAT3IL-11JAK1, JAK2, TYK2STAT3IL-12JAK 2, TYK2STAT4IL-23TYK2, JAK2STAT3, STAT4IL-27JAK1, JAK2, TYK2STAT1, STAT2, STAT3, STAT4, STAT5GHJAK 2STAT3, STAT5aEPOJAK 2STAT5TPOJAK 2STAT1, STAT3, STAT5LeptinJAK 2STAT3, STAT5aG-CSFJAK 2STAT5*G-CSF* granulocyte-colony stimulating factor, *IL* interleukin, *TPO* , *TYK* tyrosine kinase Table 2Type II cytokine receptors, ligands, and associated Janus kinase (JAK) and signal transduction and activator of transcription (STAT) moleculesLigand/cytokineAssociated JAKAssociated STATIFNα/βJAK1, TYK2STAT1, STAT2, STAT4, sometimes STAT3IFNγJAK1, TYK2STAT1IL-10JAK1, JAK2, TYK2STAT135IL-19JAK1, JAK2, TYK2STAT3IL-20JAK1, JAK2, TYK2STAT3IL-22JAK1, JAK2, TYK2STAT1, STAT3, STAT5IL-24JAK1STAT3IL- 28JAK1, TYK2STAT1, STAT2, STAT3, STAT4, STAT5IL-29JAK1, TYK2STAT1, STAT2, STAT3, STAT4, STAT5*IFN* interferon, *IL* interleukin, *TYK* tyrosine kinase

There are seven members of the mammalian STAT family: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. As mentioned above, upon activation of JAK-associated cytokine receptors, cytosolic STATs undergo tyrosine phosphorylation and dimerize. However, it is important to recognize a number of additional non-canonical roles for STATs. For example, STATs act not only as homodimers or heterodimers, but also as tetramers \[[@CR29]\]. STATs can be phosphorylated by kinases other than JAKs, including Flt3R and pyruvate kinase \[[@CR29]\]. In addition to tyrosine phosphorylation, STATs undergo serine phosphorylation in response to various external stimuli, which can augment transcriptional responses \[[@CR30]\]. Serine phosphorylation also appears to be important for the ability of certain STATs to promote oxidative phosphorylation in mitochondria \[[@CR29]\]. Finally, non-phosphorylated STATs are capable of dimerizing and acting as transcriptional regulators \[[@CR31], [@CR32]\]. STATs do not physically associate with a specific cytokine receptor but can be phosphorylated on specific tyrosine and serine residues. This results in a certain degree of functional overlap between STATs. Each member of the STAT family can be activated by multiple cytokines and their associated JAKs \[[@CR33]\], and, in certain situations, one STAT protein can transmit signals that would normally be transduced by a different STAT.

Implications of the JAK--STAT Pathway in Inflammatory and Autoimmune Diseases {#Sec4}
=============================================================================

Mutations and polymorphisms in *JAK* and *STAT* genes have been linked with several human diseases, which is not surprising as a large number of cytokines and soluble factors signal through the JAK--STAT pathway \[[@CR5]\]. Hematopoietic growth factors, including erythropoietin and thrombopoietin, signal through JAK2 \[[@CR25]\], thus gain-of-function (GOF) mutations in *JAK2* cause hematologic disorders. The most extensively described *JAK2* mutation, V617F, causes polycythemia vera, essential thrombocythemia, and myelofibrosis \[[@CR34], [@CR35]\]. Somatic GOF mutations in *JAK1* and *JAK3* are also associated with hematologic malignancies such as T-cell acute lymphoblastic leukemia and solid organ malignancies such as breast cancer \[[@CR36]--[@CR38]\].

JAK1 and JAK2 deficiency phenotypes have not been described in humans, likely because the phenotype is incompatible with life: loss-of-function (LOF) mutations in either JAK is embryonically lethal in mice \[[@CR39]\]. LOF *TYK2* mutation causes a milder immunodeficiency characterized by susceptibility to viral infection \[[@CR40], [@CR41]\] because cells cannot respond to interferon (IFN)-γ or IFNα/β \[[@CR42]\]. LOF mutations in *JAK3* cause autosomal recessive severe combined immunodeficiency, which recapitulates the phenotype observed in patients with mutations in the γc subunit \[[@CR41], [@CR43]\]. T-cell and natural killer (NK) cell maturation are profoundly impaired given the importance of γc cytokines such as IL-7 and IL-15 in their development and B-cell functions are also affected. Patients present with severe recurrent infection, failure to thrive, atopic dermatitis, and chronic diarrhea. At this time, the only definitive treatment for this disease is hematopoietic stem cell transplantation. Because JAK3 is highly expressed in immune cells, patients with autosomal recessive severe combined immunodeficiency are spared from extra-immune disease manifestations. This observation formed the basis for interest in JAK3 blockade as a potential immunosuppressive therapy \[[@CR5]\] with limited off-target effects.

*STAT1* mutations resulting in either LOF or GOF have been described. Autosomal dominant LOF mutations cause Mendelian predisposition to mycobacterial diseases \[[@CR33]\] because responses to IFNγ are impaired \[[@CR44]\]: the mutation is dominant negative for type II IFN responses. However, signaling downstream of IFNα/β is unaffected because the mutation is autosomal recessive for type I IFN signaling. Therefore, heterozygous patients are not susceptible to viral infection. Complete biallelic STAT1 deficiency, by contrast, is purely autosomal recessive for type I and II IFN signaling. Affected patients therefore exhibit fatal susceptibility to viral disease in addition to mycobacterial infections \[[@CR45]\]. GOF *STAT1* mutations cause chronic mucocutaneous candidiasis because increased signaling downstream of IFNγ inhibits IL-17 production, ultimately causing defective responses to fungal infection. Chronic mucocutaneous candidiasis patients are also predisposed to autoimmunity, and GOF *STAT1* mutations have been reported to cause a number of other autoimmune manifestations \[[@CR46]\].

LOF mutation in the *STAT2* gene causes increased susceptibility to viral infection and has also been described as a cause of sepsis-like syndrome following immunization with a live viral vaccine \[[@CR47], [@CR48]\]. This is consistent with the role of STAT2 in signaling downstream of type I IFNs, which are critical for immune responses to virus.

STAT3 signals downstream of IL-6 and is critical for the differentiation of T-helper (Th)17 cells, which secrete cytokines such as IL-17 and IL-22 \[[@CR49], [@CR50]\], among others. IL-17 is critical for immune responses to extracellular bacteria and fungi, and IL-22 promotes barrier integrity \[[@CR51], [@CR52]\]. Dominant-negative *STAT3* mutations cause hyper immunoglobulin E syndrome, also known as Job's syndrome, which is characterized by recurrent sinopulmonary infections, mucocutaneous candidiasis, dermatitis, elevated serum immunoglobulin E levels, and connective tissue abnormalities \[[@CR53]\]. Activating mutations in *STAT3*, by contrast, cause early-onset autoimmune disease \[[@CR54]\] with neonatal diabetes and autoimmune lymphoproliferative disease \[[@CR55]\]. This phenotype is driven by increased STAT3 transcriptional activity, concomitant defective STAT1/5 phosphorylation, and reduced differentiation of regulatory T cells, which are important for immune tolerance \[[@CR55]\]. Somatic *STAT3* mutations are also associated with a broad range of hematologic and solid organ malignancies, which make STAT3 blockade an active area of research for therapeutic agents \[[@CR56], [@CR57]\].

There are two *STAT5* genes, *STAT5A* and *STAT5B*. STAT5B signals downstream of many cytokines critical for immune cell growth and immune response and is particularly important for T and NK cells. As expected, LOF *STAT5B* mutations cause immunodeficiency \[[@CR58]\]. However, STAT5 is also crucial for the differentiation and function of regulatory T cells, which constrain autoreactive immune responses. Thus, patients with *STAT5B* deficiency develop autoimmune disease. Moreover, because growth hormone signals through STAT5, the clinical spectrum of *STAT5B* deficiency also includes dwarfism \[[@CR59]\].

The variety of pathology caused by *JAK* and *STAT* mutations dramatically illustrates the criticality of JAK--STAT signaling both for the normal and aberrant immune responses. Furthermore, a large body of genome-wide association studies also implicates the JAK--STAT pathway in the pathogenesis of common rheumatologic diseases \[[@CR33]\]. For example, *JAK2* polymorphisms are associated with Behçet's disease, while single nucleotide polymorphisms in the *TYK2* gene have been implicated in Crohn's disease (CD) and lupus \[[@CR25], [@CR60], [@CR61]\]. *STAT3* polymorphisms are linked to CD, psoriasis, and Behcet's disease \[[@CR62], [@CR63]\], whereas RA and systemic lupus erythematosus (SLE) are associated with *STAT4* polymorphisms \[[@CR64]\], and *STAT6* polymorphisms have been linked to RA, atopy, and asthma \[[@CR65]\].

Inhibitors of the JAK--STAT Pathway {#Sec5}
===================================

What we have described so far illustrates the importance of JAKs and STAT in the homeostasis of the immune system and provides the rationale for targeting JAK--STAT signaling to treat autoimmune and inflammatory diseases. The potential of JAK inhibition as a therapeutic strategy was recognized in the 1990s \[[@CR66]\] and fewer than 20 years later two small-molecule Jakinibs were approved by the US Food and Drug Administration (FDA): ruxolitinib for the treatment of myeloproliferative neoplasm and tofacitinib for the treatment of RA. Recently tofacitinib received positive opinion from European Medicine Agency (EMA) for its use in RA \[[@CR67]\]. Current Jakinibs act by competitively blocking the adenosine triphosphate-binding site in the JH1 domain through non-covalent interactions \[[@CR5]\]. Structural similarities of this binding site to the active domains of several other Tyrosine kinases presented a challenge for the development of a compound that would specifically block JAKs without off-target effects \[[@CR5]\]. Furthermore, given the high conservation of the JH1 domain among JAKs, developing a Jakinib that would selectively block one JAK was even more challenging \[[@CR5]\]. Despite these difficulties, multiple Jakinibs have been developed with reasonable specificity \[[@CR5]\] and it has become apparent that pan-Jakinibs, with activity against multiple JAKs, are efficacious with an acceptable adverse-effect profile. It is still unclear if selective inhibition of a specific JAK translates into therapeutic specificity \[[@CR16]\].

First-Generation Jakinibs {#Sec6}
-------------------------

### Tofacitinib {#Sec7}

Tofacitinib was the first Jakinib approved for use in autoimmune diseases. It is a JAK1/JAK3 inhibitor with some activity against JAK2 \[[@CR5], [@CR16], [@CR68]\] and negligible activity towards TYK2 \[[@CR69]\].

*Metabolism and pharmacokinetics* The majority of the metabolism of tofacitinib occurs via cytochrome P450 (CYP) 3A4 and, to a lesser extent, CYP2C19 \[[@CR70]\]. In vitro CYP3A4 inhibition with ketoconazole resulted in over 70% inhibition of metabolism \[[@CR70]\], which supports in vivo data estimating a 103% increase in the tofacitinib area under the concentration-time curve (AUC) following ketoconazole administration \[[@CR71]\]. Drug interaction studies with fluconazole also showed significant increases in the maximum plasma concentration (*C* ~max~) and AUC of tofacitinib, resulting in dosing adjustment recommendations in the package insert for concomitant use with strong CYP3A4 inhibitors or moderate inhibitors of CYP3A4 and strong inhibitors of CYP2C19 \[[@CR72], [@CR73]\]. Interaction studies with rifampin, a CYP3A4 inducer, yielded lower *C* ~max~ and AUC values for tofacitinib; however, the pharmacodynamic and clinical significance of these changes are unknown \[[@CR74]\]. Tofacitinib is not an inhibitor of CYP3A4 itself, as evidenced in a lack of alteration of midazolam pharmacokinetics, a CYP3A4 substrate, when co-administered with tofacitinib \[[@CR75]\].

Tofacitinib extended release, the recently FDA-approved formulation suitable for once-daily dosing, relies on extrudable core system osmotic-delivery technology, which confers improved upper limits of drug loading vs. bilayer push-pull osmotic tablets \[[@CR76]\]. The extended-release formulation provides equivalent total systemic exposure, *C* ~max~, and minimum plasma concentration when compared with the immediate-release tablet dosed at 5 mg twice daily (BID) \[[@CR76]\]. As expected, time to *C* ~max~ and elimination half-life are prolonged for the extended-release formulation \[[@CR76]\]. Pharmacokinetic considerations and implications for drug interactions of the FDA-approved Jakinibs are shown in Table [3](#Tab3){ref-type="table"}.Table 3Pharmacokinetic properties of the selected Janus kinase (JAK) inhibitorsJakinibAbsorption (*T* ~max~), hMetabolismActive metabolitesElimination half-life, hExcretionTofacitinib IR1Gut bioavailability 93%CYP3A4CYP2C19Minimal; \<10% drug-related activity1/10 potency for JAK1 and JAK 3 vs. parent molecule\~3\~30% renal excretionTofacitinib XR4CYP3A4CYP2C19Same as IR formulation\~5.9Same as IR formulationRuxolitinib2CYP3A4CYP2C9Yes\~3Negligible renal excretionBaricitinib1.5 post-dose\~8\~66% renal excretion*CYP* cytochrome P450, *IR* immediate releases, *T* ~*max*~ time to maximum plasma concentration, *XR* extended release

Topical tofacitinib ointment is currently being studied for plaque psoriasis. Pharmacokinetic data from a phase IIa trial showed quantifiable systemic concentration of the drug in 60% of the patients at one time point. The two different formulations of 2% tofacitinib ointment, composed of different vehicles, had time to maximum plasma concentration values of 0.5 and 2 h \[[@CR77]\].

*Efficacy of tofacitinib in rheumatoid arthritis* Various phase II and phase III trials showed the safety and effectiveness of tofacitinib as monotherapy and in combination with other disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis \[[@CR78]--[@CR89]\] (Table [4](#Tab4){ref-type="table"}). The dose of tofacitinib in the reported phase II studies ranged between 1 and 30 mg BID. A dose-ranging study by Tanaka and colleagues showed incremental response in American College of Rheumatology 20% (ACR 20) with increasing doses of tofacitinib \[[@CR79]\], but this observation was not confirmed in other clinical trials \[[@CR80]\]. Such trials, including the phase III trials under the oral RA trials (ORAL) series, showed increased attainment of ACR 20 response with tofacitinib relative to placebo. Other measures of improvement as defined by the American College of Rheumatology (ACR 50, ACR 70), and functional status measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the 36-Item Short Form Health Survey were also improved (Table [4](#Tab4){ref-type="table"}).Table 4Phase II and III trials on tofacitinib in rheumatoid arthritis (RA)Study nameNo. of subjectsParticipantsInterventionStudy durationEfficacyAdverse eventsSerious adverse eventsPhase IIa, Kremer et al. \[[@CR78]\]264Active RA, inadequate/toxic response to MTX, etanercept, infliximab or adalimumabTofacitinib 5, 15, and 30 mg twice daily or placebo × 6 weeks12 weeksACR 20 response rates 70.5, 81.2, and 76.8% in 5-, 15-, and 30-mg groups compared with 29.2% in placebo (*p* \< 0.001)Infections (influenza, URI, UTI) 30.4% in 15-mg and 30-mg group vs. 26.2% in placeboIncrease in mean LDL, HDL, and Cr (0.04--0.06 mg/dL). Sporadic neutropenia, anemiaGastroenteritis in 1 patient on tofacitinib 15 mg twice daily; severe leukopenia in 1 patient receiving tofacitinib 30 mg twice dailyPhase II, Tanaka et al. \[[@CR79]\]140Active RA on stable MTX, inadequate response to MTX aloneTofacitinib 1, 3, 5, and 10 mg twice daily or placebo × 12 weeks. MTX continued12 weeksACR20 response rates: 1 mg twice daily, 64.3%; 3 mg twice daily, 77.8%; 5 mg twice daily, 96.3%; and 10 mg twice daily, 80.8% vs. placebo, 14.3%. (*p* \< 0.0001)Significant improvement in ACR50, ACR70, HAQ-DI, and DAS28-CRPNasopharyngitis, transaminitis, increase in Cr, LDL, HDL, total cholesterolFoot deformity, osteoarthritis, femur fracture, cardiac failure, and acute dyspneaPhase IIb, Kremer et al. \[[@CR80]\]507Active RA on stable MTX, inadequate response to MTX aloneTofacitinib (20 mg/day, 1 mg twice daily, 3 mg twice daily, 5 mg twice daily, 10 mg twice daily, or 15 mg twice daily). All patients continued stable MTX dose24 weeksACR20 response on tofacitinib ≥3 mg BID significantly \> placebo 52.9% for 3 mg, 50.7% for 5 mg, 58.1% for 10 mg, 56.0% for 15 mg, and 53.8% for 20 mg and 22% in placeboImprovements in ACR50, ACR70, HAQ-DI, DAS28-CRP\>10% patients in tofacitinib group: diarrhea, URI, headache; transaminitis, increased cholesterol and serum creatinine, neutropenia, anemiaPNA, UTI, RTI; 1 death from PNA, severe anemiaPhase IIb, Fleischmann et al. \[[@CR82]\]384Active RA, failure of at least one DMARD (lack of efficacy/toxicity), only anti malarials continuedPlacebo, tofacitinib 1, 3, 5, 10, or 15 mg twice daily, or adalimumab 40 mg Q 2 weeks (total 6 injections) followed by tofacitinib 5 mg twice daily × 12 weeks24 weeksACR20 significantly improved in tofacitinib ≥3 mg groups compared with placebo. 39.2% (3 mg), 59.2% (5 mg), 70.5% (10 mg), 71.9% (15 mg) in tofacitinib group and 35.9% in adalimumab group, compared with 22.0% in placebo improvement in ACR50, and ACR70, DAS28-CRP/DAS28-ESRUTI (7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%)PNA, pneumococcal sepsis, acute pyelonephritis severe anemiaPhase III, Fleischmann et al. \[[@CR83]\] (ORAL solo)611Active RA inadequate response to ≥1 DMARD non-biologic or biologic, off of all DMARD except antimalarialdrugs, NSAIDs, low-dose steroid permittedRandomly assigned, 4:4:1:1, tofacitinib 5 mg twice daily × 6 months; Tofa 10 mg twice daily × 6 months; placebo × 3 months, then tofacitinib 5 or 10 mg twice daily × 3 months6 months; primary efficacy endpoints at 3 monthsACR 20 response significantly improved in tofacitinib groups vs. placebo (*p* \< 0.001). 59.8% in the 5-mg tofacitinib group and 65.7% in the 10-mg tofacitinib group vs. 26.7% in placebo groups, Reductions in HAQ-DI (*p* \< 0.001)Headache, URI elevations in LDL, neutropeniaCCF, thrombocytopenia, cellulitis, lung Ca, uterine leiomyoma, COPD, pulmonary fibrosis, sleep apnea, PE, DVT, 1 death from heart failurePhase III, Burmester et al. \[[@CR84]\] (ORAL step)399Moderate-to-severe RA, inadequate response to TNF inhibitors. NSAIDS, low-dose steroid permittedRandomly assigned 2:2:1:1 tofacitinib 5 mg twice daily; 10 mg twice daily; or placebo, MTX continued. At 3 months, placebo advanced to tofacitinib 5 mg twice daily or 10 mg twice daily6 monthsACR20 response rates 41.7% for tofacitinib 5 mg twice daily and 48.1% for tofacitinib 10 mg twice daily vs. 24.4% for placebo. Statistically significant improvements in HAQ-DI and DAS28Diarrhea nasopharyngitis, headache, and UTI, URI nasopharyngitis bronchitisPanniculitis (*n* = 1); bronchopneumonia (*n* = 1) in 5 mg twice daily; pyelonephritis (*n* = 1) in 10 mg twice daily and diverticulitis (*n* = 1), aspiration PNA (*n* = 1) in 5 mg twice daily, pulmonary embolism (*n* = 1) in 10 mg twice dailyPhase III, Vollenhoven et al. \[[@CR85]\] (ORAL-standard)717Active disease, inadequate response to MTX glucocorticoids (≤10 mg prednisone equivalent per day), NSAIDs permittedRandomly assigned to tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, adalimumab 40 mg every 2 weeks, or placebo. At month 3, non-responders in placebo group switched to tofacitinib 5 mg or 10 mg; at month 6, all patients on placebo switched to tofacitinib12 months, results reported at 6 monthsACR 20 on 5 or 10 mg of tofacitinib were 51.5 and 52.6%, respectively, and 28.3% for placebo (*p* \< 0.001). ACR20 47.2% for adalimumab greater reductions in HAQ-DI at month 3; higher % of patients with DAS28-ESR below 2.6 at month 6 in active-treatment groups than in the placebo groupIncrease in LDL, HDL, neutropenia, anemia, transaminitisAV block, MI, CCF, retinal detachment, GI bleed, cellulitis, herpes zoster, PNA, pulmonary TB, UTI, osteomyelitis, septic shock, fractures, cervical, ovarian and lung Ca, benign neuroma, cholesteatoma, salivary gland neoplasmPhase III, Kremer et al. \[[@CR86]\] (ORAL sync)792Active RA, inadequate response to ≥1 non-biologic or biologic DMARDs and continue background non-biologic DMARDsRandomly assigned 4:4:1:1 to tofacitinib 5 or 10 mg twice daily, or placebo advanced to tofacitinib, 5 or 10 mg twice daily12 monthsACR20 response rates (month 6) for the tofacitinib 5-mg and 10-mg groups and placebo groups; were 52.1, 56.6 and 30.8%, respectively (*p* *≤* 0.001), HAQ-DI DAS28-ESR less than 2.6 response superior in tofacitinib groups versus placeboNeutropenia, anemia, LDL, HDL, serum creatinine increased in tofacitinib groupsIn tofacitinib groups, 2 cases of TB, 2 cases of other opportunistic infections, 3 cardiovascular events, and 4 deaths occurredPhase III, van der Heijde et al. \[[@CR87]\] (ORAL scan)797Active RA, evidence of ≥3 joint erosions or, IgM RF or anti-CCP, on stable doses of MTXLow-dose corticosteroids and NSAIDs allowedPrior use of biologic or non-biologic DMARDs permittedRandomized 4:4:1:1 to tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo to tofacitinib 5 mg twice daily, and placebo to tofacitinib 10 mg twice daily. At month 3, non-responder placebo-treated patients advanced to tofacitinib; remaining placebo-treated patients advanced at 6 months24 months (24-month interim analysis report)ACR20 improvement in tofacitinib 5 and 10 mg twice daily 51.5 and 61.8%, vs. 25.3% in placebo (*p* \< 0.0001). At month 6, changes in total modified Sharp/van der Heijde score for tofacitinib 5 and 10 mg twice daily 0.12 and 0.06, respectively, vs. 0.47 for placebo (*p* = 0.0792 and *p* \< 0.05, respectively)At month 3, changes in HAQ-DI score for tofacitinib was better than placeboAt month 6, rates of remission for tofacitinib at 5 and 10 mg twice daily were 7.2 and 16.0% vs. 1.6% for placeboLymph node TB (tofacitinib 10 mg twice daily) esophageal candidiasis (tofacitinib 5 mg twice daily and 10 mg twice daily), anemia, neutropenia, increased HDL, LDL, transaminitisPneumo-cystis jiroveci pneumonia (tofacitinib 5 mg twice daily), CMV sialadenitis (tofacitinib 10 mg twice daily), and CMV viremia (tofacitinib 10 mg twice daily), ARF, ARDS, cardiovascular events, malignanciesPhase III, Lee et al. \[[@CR88]\] (ORAL start)958Active RA no exposure to therapeutic doses of MTX with ≥3 distinct joint erosions on hand and wrist or foot radiograph, or (+) IgM RF or anti-CCPAbRandomly assigned to tofacitinib 5 or 10 mg of twice daily or MTX up to 20 mg per week over 8 weeks6 monthsACR 20 response at 6 month: 71.3% in 5-mg group and 76.1% in 10-mg group 50.5% in the MTX groupMean changes in modified total Sharp score from baseline to month 6 were significantly smaller in tofacitinib groups than in the MTX groupIncreases in creatinine, LDL, HDL, neutropenia, lymphopenia, anemiaHerpes zoster, malignancy non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, prostate cancer, Burkitt's B-cell lymphoma, and colon cancer*ACR20/50/70* American College of Rheumatology 20, 50 and 70% improvement criteria, *ARDS* acute respiratory distress syndrome, *ARF* acute renal failure, *AV block* atrioventricular block, *Ca* carcinoma, *CCF* congestive cardiac failure, *CCP* cyclic citrullinated peptide, *CMV* cytomegalovirus, *COPD* chronic obstructive pulmonary disease, *Cr* serum creatinine, *CRP* C-reactive protein, *DAS28* Disease Activity Score28, *DMARDs* disease-modifying anti-rheumatic drugs, *DVT* deep vein thrombosis, *ESR* erythrocyte sedimentation rate, *GI bleed* gastrointestinal bleed, *HAQ-DI* Health Assessment Questionnaire Disability Index, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *MI* myocardial infarction, *MTX* methotrexate, *NNT* number needed to treat, *NSAID*s non-steroidal anti-inflammatory drugs, *PE* pulmonary embolism, *PNA* pneumonia, *PRO* patient-reported outcome, *PtGA* patient global assessment, *RF* rheumatoid factor, *RTI* respiratory tract infections, *SF-36* 36-Item Short Form Health Survey, *TNF* tumor necrosis factor, *TB* tuberculosis, *URI* upper respiratory tract infections, *UTI* urinary tract infections

Several studies have examined the effect of tofacitinib on structural joint disease, assessed radiographically, with promising results. A phase II randomized controlled trial compared the effects of tofacitinib monotherapy, tofacitinib and methotrexate combination therapy, and methotrexate monotherapy on the musculoskeletal system. Magnetic resonance imaging (MRI) outcomes were reported as Outcome Measures in Rheumatology Clinical Trials RA MRI score (RAMRIS), quantitative RAMRIS, and dynamic contrast-enhanced MRI \[[@CR90]\]. The study showed significant improvement in RAMRIS bone marrow edema at 6 months and improvement in synovitis scoring at 3 months in both tofacitinib monotherapy and tofacitinib with methotrexate combination therapy compared with methotrexate monotherapy. A significant difference was noted in synovitis scores by quantitative RAMRIS at 3 months. Erosive damage was significantly lower at 6 and 12 months in both the tofacitinib monotherapy and combination therapy groups compared with methotrexate monotherapy \[[@CR91]\]. The phase III ORAL-Scan trial also used radiographic outcomes and showed slower rates of radiographic progression of disease in patients treated with tofacitinib at 5 or 10 mg BID with background methotrexate as measured by erosion score and joint space narrowing scores. The change in the joint space narrowing score was statistically significant at 12 months \[[@CR88]\].

The long-term efficacy of tofacitinib in moderate to severe RA in 4000 patients was reported in the ORAL sequel study, which showed continued efficacy of the drug over 48 months as measured by ACR 20/50/70, Disease Activity Score 28-4-Erythrocyte Sedimentation Rate (DAS28-4-ESR), and HAQ-DI. \[[@CR92]\]. Finally, a long-term extension trial collecting data on open-label tofacitinib following blinded treatment with adalimumab or tofacitinib for moderate to severe RA was reported recently, from patients in the ORAL standard and ORAL sequel trials. Results supported long-term efficacy of tofacitinib, with improved physical function and disease signs and symptoms as measured by ACR response criteria and DAS28-ESR in tofacitinib-treated patients \[[@CR93]\].

*Tofacitinib in psoriasis and psoriatic arthritis* Many inflammatory cytokines critical to the pathogenesis of psoriasis signal through the JAK--STAT pathway, including type I/II IFNs, IL-12, IL-22, and IL-23 \[[@CR94]\]. Thus, it is not unexpected that Jakinibs are an effective treatment for psoriatic skin and joint disease.

A phase I trial conducted on medically stable patients with mild to moderate psoriasis demonstrated the efficacy of tofacitinib at a dose of 10 mg BID or higher, as measured by patient global assessment and histology \[[@CR95]\]. A subsequent phase II trial using a range of 2--15 mg BID doses of tofacitinib to treat more severe plaque disease also demonstrated statistically significant improvement in the Psoriasis Area and Severity Index (PASI) 75 and in other outcome measures including physician global assessment, PASI 50, and PASI 90 compared with placebo \[[@CR96]\].

Phase III trials (OPT Pivotal 1 and OPT Pivotal 2 and Long Term Extension study) using oral tofacitinib at 5- and 10-mg BID dosing in patients with moderate to severe plaque psoriasis demonstrated efficacy of both doses over placebo as measured by standard criteria described above. The efficacy was maintained at 2 years in the long-term extension trial. The higher dose of 10 mg BID was found to be more efficacious \[[@CR97], [@CR98]\]. Indeed, comparison of both 5- and 10-mg BID doses with weekly etanercept established non-inferiority of only the 10-mg dose, whereas the 5-mg dose was inferior to TNF blockade \[[@CR99], [@CR100]\]. It was concluded from this result that the effective dose of tofacitinib in psoriasis would be 10 mg BID. Owing to potential safety concerns regarding the use of higher doses of tofacitinib, the drug failed to obtain FDA approval for the treatment of psoriasis. It remains to be seen whether this decision will be re-evaluated as more extensive safety data from long-term extension studies clarify the long-term risks of such treatment.

A 52-week, phase III, multisite, randomized, double-blind trial was conducted in 16 centers in Japan to study the efficacy, safety, and tolerability of tofacitinib in the treatment of psoriatic arthritis. The results showed that 62.8 and 72.7% of plaque psoriasis patients on 5 and 10 mg of tofacitinib, respectively, achieved a PASI 75. While only 12 patients had joint disease, 100% of these patients achieved ACR 20 response. Preliminary results from the larger phase III OPAL-Broaden and OPAL-Beyond studies were similarly encouraging, meeting their primary efficacy endpoints for DMARD-refractory and anti-TNF-refractory psoriatic arthritis \[[@CR101]\]. These studies demonstrated that tofacitinib may represent a promising therapy for psoriatic arthritis, although more extensive results and future long-term studies may be needed to clarify the effects of tofacitinib on structural joint disease \[[@CR102]\].

*Topical tofacitinib in psoriasis* A phase IIa, multi-center, double-blind, vehicle-controlled study was conducted to evaluate the efficacy, safety, tolerability, and systemic pharmacokinetics of topical tofacitinib in mild-to-moderate plaque psoriasis. Two different tofacitinib ointment formulations were assessed, both were administered BID for 4 weeks to a single fixed 300-cm^2^ area with one target plaque with or without one or more non-target plaques and normal skin. The primary endpoint, defined as the percentage change from baseline in the Target Plaque Severity Score, showed statistically significant improvement by about 50% only for one of the ointments at week 4 \[[@CR77], [@CR103]\].

*Tofacitinib in inflammatory bowel disease* Inflammatory bowel disease (IBD) comprises two major distinct entities: ulcerative colitis (UC) and CD. While the two forms of IBD exhibit many common clinical features, they are pathophysiologically distinct and may not respond to tofacitinib in the same way. Although a full understanding of IBD immunopathogenesis is lacking, it appears that both forms result from dysregulated immune responses. The role of type I/II cytokines in IBD is well established: IL-12, type II IFN, and IL-6 promote the function of pathogenic innate lymphoid cells and T cells \[[@CR104]\]. However, patients are also immunodeficient: they are unable to constrain pathogenic microbiota. Moreover, anti-inflammatory cytokines such as IL-22 and IL-17A may have a protective role \[[@CR104]\]. Thus, type I/II cytokine blockade may have unintended consequences.

Tofacitinib is being considered for the treatment of UC. After promising results from initial phase II trials \[[@CR105]--[@CR107]\], the efficacy of tofacitinib as induction therapy was assessed in two phase III trials in patients with moderate-to-severe UC (OCTAVE Induction 1 and 2), which were recently completed. Preliminary reports indicate that the trials met their primary and secondary endpoints, although full results are not yet available \[[@CR108]\]. The OCTAVE Sustain trial, which examines the efficacy of tofacitinib as maintenance therapy, and the long-term extension OCTAVE open trial will provide more data regarding the efficacy of JAK inhibition in the treatment of UC. Approval of tofacitinib for UC will likely depend on the final outcomes of these studies \[[@CR109]\].

Results for patients treated with tofacitinib for CD are less clear. A randomized, multi-center, phase II clinical trial including 139 patients with moderate-to-severe active CD receiving tofacitinib 1, 5, or 15 mg or placebo BID for 4 weeks did not show clinical efficacy. However, the study showed a statistically significant reduction in serum C-reactive protein (CRP) and fecal calprotectin levels in subjects receiving the 15-mg dose. The reasons for the negative results of the trial are unclear but may be related to the short study duration, possibly limiting the ability of tofacitinib to show any significant improvement in clinical response \[[@CR109], [@CR110]\]. Preliminary data from subsequent studies indicate a small effect for tofacitinib treatment in CD \[[@CR111]\]; however, it is not clear whether such effects are clinically significant. Results also indicate that tofacitinib may be effective as maintenance therapy \[[@CR112]\], although further data from an ongoing long-term clinical trial will answer this question more definitively (<http://www.clinicaltrials.gov> NCT01393626).

### Ruxolitinib {#Sec8}

The first FDA-approved Jakinib, ruxolitinib is a JAK1 and JAK2 inhibitor \[[@CR5]\] with moderate inhibitory activity against Tyk2 \[[@CR113]\]. As mentioned above, ruxolitinib was developed for the treatment of polycythemia vera and intermediate- and high-risk primary myelofibrosis \[[@CR33], [@CR114]\], where inappropriate activation of JAK2 underlies disease pathogenesis, and is FDA approved for these diseases. Ruxolitinib is also effective in the treatment of essential thrombocythemia \[[@CR115]\] and has been granted Breakthrough Therapy Designation for the treatment of graft vs. host disease \[[@CR116]\].

*Metabolism and pharmacokinetics* Ruxolitinib and tofacitinib have similar pharmacokinetic profiles but ruxolitinib has more active metabolites and lower renal excretion \[[@CR70]\]. Ruxolitinib is metabolized primarily by CYP3A4 and to a lesser extent, CYP2C19 (Table [3](#Tab3){ref-type="table"}). Pharmacokinetic and pharmacodynamic studies using ketoconazole and erythromycin, strong and intermediate inhibitors of CYP3A4 as well as rifampin, a CYP3A4 inducer, were conducted to determine the impact on the metabolism of ruxolitinib \[[@CR117]\]. Co-administration of ketoconazole with single-dose ruxolitinib resulted in an increase in drug exposure for ruxolitinib of 91% and a prolongation of the elimination half-life of ruxolitinib of approximately 2 h. Co-administration of erythromycin, a moderate CYP3A4 inhibitor, with ruxolitinib exhibited much less significant impact on *C* ~max~ and drug exposure of ruxolitinib. Pharmacokinetic studies of ruxolitinib with rifampin resulted in a 52% decrease in *C* ~max~ of ruxolitinib with a decrease in terminal half-life of approximately 50% \[[@CR117]\]. The pharmacodynamic impact of these interactions were assessed through an assay evaluating the extent of inhibition of STAT3 phosphorylation. Co-administration of ketoconazole resulted in a doubling of STAT3 phosphorylation inhibition, which was clinically and statistically significant. Co-administration of erythromycin and rifampin resulted in a 13% increase or a 10% decrease of pharmacodynamic activity respectively. These changes were not considered to be clinically significant \[[@CR117]\]. Further pharmacokinetic modeling studies evaluated the effect of fluconazole, a moderate inhibitor of both CYP3A4 and CYP2C19, and estimated a two-fold increase in ruxolitinib AUC with fluconazole doses of the 100--200 mg total daily dose. This same modeling study also evaluated the impact of ruxolitinib on p-glycoprotein efflux pumps and did not predict a significant impact of ruxolitinib co-administration with p-glycoprotein substrates including digoxin \[[@CR118]\].

*Use of ruxolitinib in autoimmune diseases* Studies using ruxolitinib to treat various inflammatory and autoimmune diseases have been promising. A phase IIa trial of ruxolitinib in RA showed encouraging results with improvement in ACR 20, 50, and 70 and HAQ-DI as compared with placebo after 28 days \[[@CR113], [@CR119]\]. A case of chilblain lupus erythematosus has been successfully treated with oral ruxolitinib \[[@CR120]\]. Improvement in muscle strength and skin lesions was also reported in a patient with dermatomyositis and post-polycythemia vera *JAK2* V617F-positive myelofibrosis \[[@CR121]\]. Moreover, remarkable improvements in patients with alopecia areata treated with oral ruxolitinib for 3--5 months have been reported. Comparison of biopsy samples at baseline and after 12 weeks of treatment demonstrated decreased inflammation post-treatment \[[@CR122]\].

### Topical Ruxolitinib {#Sec9}

Ruxolitinib has been reported to have significant cutaneous anti-inflammatory action \[[@CR123]\], and effects on plaque psoriasis were investigated in a small placebo-controlled clinical trial (86). Topical ruxolitinib was well tolerated and superior to placebo in reducing the plaque area \[[@CR124]\]. Topical ruxolitinib has also been reported to be useful in alopecia \[[@CR125]\].

### Baricitinib {#Sec10}

Baricitinib is another selective JAK1/JAK2 inhibitor that inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6, IL-12, IL-23, and IFNγ \[[@CR126]\].

*Metabolism and pharmacokinetics* Renal clearance is the primary route of excretion for baricitinib; therefore, the role of CYP-mediated medication interactions are thought to be minimal for this drug \[[@CR127]\]. It is speculated that the half-life would be prolonged in disease states with reduced renal function \[[@CR127]\] (Table [3](#Tab3){ref-type="table"}).

*Efficacy of baricitinib in RA* Baricitinib has progressed to phase III studies in RA. Phase IIb studies have demonstrated the efficacy of baricitinib at 4- and 8-mg dosing in RA unresponsive to methotrexate over a 12- to 24-week study period \[[@CR128], [@CR129]\]. Improvement in musculoskeletal MRI findings was demonstrated along with clinical response in a phase IIb substudy \[[@CR130]\].

Table [5](#Tab5){ref-type="table"} summarizes important phase III trials on baricitinib in RA \[[@CR131]--[@CR134]\]. The trials unequivocally established the efficacy of baricitinib in active RA with improvement in all the measures of ACR response criteria. There was significant improvement in ACR 20/50/70, DAS28, and HAQ-DI in the subjects treated with baricitinib compared with placebo. The RA-BEAM (A Study in Moderate to Severe Rheumatoid Arthriris) study demonstrated superiority of baricitinib over adalimumab, a landmark finding not achieved with any other disease-modifying agent. The long-term extension of this study at 24 and 52 weeks showed prevention of progressive radiographic structural joint damage with baricitinib \[[@CR134]\]. Similar radiographic improvement was shown in the RA-BUILD (A Study in Moderate to Severe Rheumatoid Arthritis Participants) study as well, where a change in the medial tibia stress syndrome score at week 24 was significantly lower in the baricitinib group compared with placebo \[[@CR133]\]. An interesting finding in this study was the rapid improvement in ACR criteria within a week whereas, inability to respond to the drug within 4 weeks was predictive of future failure. This information could be used to prevent unnecessary drug exposure in non-responders \[[@CR135]\].Table 5Baricitinib in rheumatoid arthritis (RA)Study nameNo.of subjectsParticipantsInterventionStudy durationEfficacyAdverse eventsSerious adverse eventsGenovese et al. \[[@CR132]\] (RA-BEACON)527Active RA with inadequate response/unacceptable side effects with ≥TNF inhibitors, other biologics DMARDs, or bothRandomly assigned in 1:1:1 baricitinib 2 or 4 mg daily or placebo for 24 weeks24 weeksBaricitinib 4, 2 mg and placebo had ACR20 response at 12 weeks 55, 49 and 27% (*p* \< 0.001). Significant difference in HAQ-DI and DAS28-CRP between higher-dose baricitinib group and placebo groupMild neutropenia, increased serum creatinine, LDL, herpes zosterFatal stroke, MI, non melanomatous skin cancersDougados et al. \[[@CR133]\] (RA-BUILD)684Active RA and inadequate response to conventional DMARDsRandomized 1:1:1 to placebo or baricitinib (2 or 4 mg) daily with stable background treatment24 weeksACR20 response at week 12 was 62% with baricitinib 4 mg, 66% in 2 mg, and 40% with placebo (*p* ≤ 0.001). Improvements in ACR50, ACR70, DAS28, CDAI, SDAI, and HAQ-DISimilar in all groups, no opportunistic infection, no GI perforationTuberculosis: 1 case, Non-melanomatous skin cancer: 1 case in baricitinib 4 mgFleischmann et al. \[[@CR131]\] (RA-BEGIN)584Active RA, no previous DMARD other than ≤3 doses of MTXRandomized 4:3:4 to MTX, baricitinib 4 mg once daily (baricitinib monotherapy), or baricitinib 4 mg QD + MTX for up to 52 weeksResults reported at 24 weeksACR20 response higher with baricitinib 4 mg monotherapy vs. MTX (77% vs. 62%, *p* ≤ 0.01). Compared with MTX, baricitinib 4 mg monotherapy produced significantly greater improvements in ACR 50, 70, CDAI, SDAI, DAS28-CRP, HAQ-DI, MTX and baricitinib 4 mg combination was not superior to baricitinib monotherapySimilar in all groupsHerpes zoster, anemia, leukopenia, transaminitisPJP, esophageal candidiasis in combination groupTaylor et al. \[[@CR134]\] (RA-BEAM)1305Active RA on stable background MTXRandomized 3:3:2 to placebo, baricitinib 4 mg once daily, or adalimumab 40 mg biweekly24 weeks, results reported at 12 and 24 weeksACR20 higher for baricitinib vs. placebo (70 vs. 40%, *p* ≤ 0.001). ACR20 with adalimumab 61%. Significant improvements in ACR 20/50/70 and HAQ-DI, DAS28, CDAI, and SDAI for baricitinib vs. placebo. Compared with ADA, baricitinib superior in ACR20 and DAS28-CRP. Diminished radiographic progression with Bari vs. placeboAnemia, leukopenia, transaminitis, 3 opportunistic infections1 case of pneumonia and 1 duodenal ulcer hemorrhage5 malignancies, 1 case of TB*ACR20/50/70* American College of Rheumatology 20, 50 and 70% improvement criteria, *ARDS* acute respiratory distress syndrome, *ARF* acute renal failure, *AV* atrioventricular, *Ca* carcinoma, *CCF* congestive cardiac failure, *CCP* cyclic citrullinated peptide, *CMV* cytomegalovirus, *COPD* chronic obstructive pulmonary disease, *Cr* serum creatinine, *CRP* C-reactive protein, *DAS28* Disease Activity Score 28, *DMARD* disease-modifying anti-rheumatic drugs, *DVT* deep vein thrombosis, *ESR* erythrocyte sedimentation rate, *GI* gastrointestinal, *HAQ-DI* Health Assessment Questionnaire-Disability Index, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *MI* myocardial infarction, *MTX* methotrexate, *NNT* number needed to treat, *NSAID*s non-steroidal anti-inflammatory drugs, *PE* pulmonary embolism, *PJP* pneumocystis jirovecii pneumonia, *PNA* pneumonia, *PRO* patient-reported outcome, *PtGA* patient global assessment, *RF* rheumatoid factor, *RTI* respiratory tract infections, *SF-36* 36-Item Short Form Health Survey, *TB* tuberculosis, *TNF* tumor necrosis factor, *URI* upper respiratory tract infections, *UTI* urinary tract infections

Following the RA-BUILD study, patient-reported outcome measures including pain, functional disability, and fatigue showed significant improvement with baricitinib therapy \[[@CR136]\]. An Extension Study in Participants with Moderate to Severe Rheumatoid Arthritis (RA-BEYOND) is currently recruiting participants. The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib RA study. The study will provide for 4 years of additional treatment with baricitinib (<http://www.clinicaltrials.gov> NCT01885078).

*Baricitinib and other diseases* Baricitinib has been shown to improve PASI 75 scores in plaque psoriasis in a phase IIb trial \[[@CR137]\]. Baricitinib is also extremely effective in the treatment of autoinflammatory diseases characterized by an IFN gene signature, such as chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome \[[@CR138]\]. Similar to ruxolitinib, baricitinib was found to be effective in alopecia areata in a patient who received this drug for the treatment of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome \[[@CR139]\].

### Oclacitinib {#Sec11}

Oclatinib is a pan-Jakinib approved for canine eczema and atopic dermatitis \[[@CR25], [@CR140]\]. The efficacy of oclacitinib for canine atopic disease hints that Jakinibs may represent a promising therapeutic strategy for the treatment of allergic diseases in humans, and preliminary results indicate that tofacitinib may also be efficacious for atopic dermatitis \[[@CR141]\]. Clinical trials are ongoing to further evaluate the efficacy of systemic and topical Jakinibs for this class of diseases.

Safety of Jakinibs: Lessons from Clinical Trials {#Sec12}
------------------------------------------------

Because Jakinibs simultaneously block signaling downstream of cytokines important for a range of physiological functions, their side effects can often be directly linked to their mechanism of action. Safety concerns include effects on hematopoiesis, innate and adaptive host defense, as well as growth. Because tofacitinib is the most extensively studied Jakinib, most available safety data are derived from clinical trials where this drug was used. These studies have demonstrated an acceptable safety profile \[[@CR33]\], and the safety profiles of other Jakinibs appear comparable.

Infection secondary to immunosuppression represents a major concern in Jakinib-treated patients. Common side effects in RA clinical trials included infections such as nasopharyngitis or upper respiratory infections, bronchitis, and gastroenteritis. A number of opportunistic infections such as herpes zoster, tuberculosis, cellulitis, panniculitis, septic shock, and osteomyelitis were also reported \[[@CR3], [@CR142]\]. The observed risk was similar to that with other DMARDS, and a retrospective meta-analysis of pooled data from all the trials and extension studies indicated a lower risk of infection in tofacitinib-treated patients than for patients treated with biological DMARDs \[[@CR142]\]. The exception to this is varicella zoster virus, for which the risk of reactivation is substantially higher in tofacitinib-treated patients \[[@CR143], [@CR144]\]. This increased risk may be in part owing to the importance of JAK3-dependent cytokines in driving the development and functions of NK cells, which are important for controlling viral infections such as herpes zoster \[[@CR142]\]. However, NK cell counts are not markedly reduced in tofacitinib-treated patients; therefore, the etiology of zoster reactivation may be related to NK cell function or to effects on a different leukocyte population. Among other serious opportunistic infections, BK viremia and nephropathy have been reported in kidney transplant recipients treated with high-dose tofacitinib (30 and 15 mg BID) in combination with mycophenolate mofetil \[[@CR145]\]. A larger multi-center clinical trial also showed a higher incidence (14--18%) of BK nephropathy in renal transplant recipients treated with tofacitinib compared with cyclosporine (6%) \[[@CR146]\], also in combination with mycophenolate mofetil and at relatively high doses. Progressive multifocal leukoencephalopathy has been reported in a 75-year-old man treated with ruxolitinib for myelofibrosis \[[@CR147]\].

Like infectious complications, Jakinib-driven cytopenias were expected because many hematopoietic growth factors including erythropoietin and granulocyte macrophage-colony stimulating factor signal through JAK2. Neutropenia and anemia were indeed observed albeit sporadically. A higher incidence of mild-to-moderate anemia, leukopenia, neutropenia, lymphopenia, and thrombocytopenia was observed in patients receiving tofacitinib 30 mg compared with patients on lower doses of tofacitinb \[[@CR78]\]. In patients taking lower doses, cytopenias were typically mild and did not necessitate discontinuation of the drug.

One particular concern with long-term suppression of the JAK--STAT pathway is the possible development of malignancies. Both type I and II IFNs play an important role in the process of immunoediting, which is critical for the anti-tumor immune response \[[@CR148]\]. In post-transplant patients treated with tofacitinib, the risk of lymphoproliferative malignancy was increased by JAK inhibition \[[@CR149]\]. However, the phase II and III trials for autoimmune diseases have not shown an increased cancer risk associated with tofacitinib treatment \[[@CR92]\]. The incidence of malignancy, including lymphoma and non-melanomatous skin cancer, is similar to that seen with other biologics.

The increase in low-density lipoprotein (LDL), high-density lipoprotein (HDL), and a few cardiovascular events such as atrioventricular block, congestive heart failure, and myocardial infarction were observed in tofacitinib-treated patients. However, long-term extension studies have not shown evidence of an increased rate of cardiovascular events \[[@CR92]\]. Combined data from phase III trials on tofacitinib demonstrated stabilization of lipid levels after 3 months of treatment and the incidence of cardiovascular adverse events was similar to placebo \[[@CR150]\]. The effect of tofacitinib on the lipid profile is similar to tocilizumab and may be secondary to blocking IL-6 signaling. The physiological role of IL-6 on hepatic lipid metabolism is complex and incompletely understood \[[@CR151]\]. IL-6 is known to cause insulin resistance and high IL-6 levels have been noted in obesity. IL-6 also support the redistribution of fatty acids from the blood to peripheral tissues, which results in low serum levels of LDL, HDL, and triglycerides \[[@CR25]\]. To date, long-term extension studies have not shown an increase in major cardiovascular events in tofacitinib-treated patients relative to those treated with placebo \[[@CR150], [@CR152]\]. Tofacitinib was actually shown to reduce vascular stiffness in RA patients in a small study of 18 patients \[[@CR153]\]. Assessment of cholesterol and lipoprotein kinetics in RA patients before and after tofacitinib treatment in comparison to healthy volunteers revealed increased levels of cholesterol in RA patients after treatment and is secondary to reduced cholesterol ester catabolism and anti-atherogenic HDL level improvement \[[@CR154]\].

Other changes in laboratory parameters included sporadic elevations in transaminases and creatinine. Clinically significant hepatic and renal compromise have not been reported; however, \[[@CR92]\] a phase I randomized controlled trial assessed changes in serum creatinine and glomerular filtration rate in RA patients treated with tofacitinib and compared them with patients who received placebo. Tofacitnib treatment caused mild increases in creatinine (5%) and decreases in glomerular filtration rate (8%), which reversed rapidly upon drug discontinuation \[[@CR155]\].

Next-Generation Jakinibs {#Sec13}
------------------------

Whereas first-generation Jakinibs including tofacitinib have shown efficacy in the treatment of inflammatory conditions like RA, nonselective pan-JAK blockade can be associated with unwanted adverse effects such as cytopenias. This raises the potential utility of next-generation Jakinibs with selective inhibitory activity for a specific JAK (Fig. [3](#Fig3){ref-type="fig"}), which, in principle might be used to treat selected autoimmune disorders with fewer adverse effects \[[@CR156]\]. However, increased selectivity may also translate into reduced efficacy.

### Decernotinib (VX-509) {#Sec14}

Decernotinib is a next-generation Jakinib with in vitro kinase assays demonstrating five-fold selectivity towards JAK3 compared with JAK1, JAK2, and TYK2 \[[@CR157]\]. Decernotinib showed promising results in animal models of autoimmune diseases \[[@CR156]\] and was therefore moved into clinical trials for the treatment of RA.

*Metabolism and pharmacokinetics* Decernotinib possesses a unique pharmacokinetic profile with potential implications for medication interactions. The major metabolite of decernotinib, M3, acts as a potent inhibitor of CYP3A4 \[[@CR158]\]. CYP3A4 is the most prevalent hepatic CYP enzyme and is implicated in metabolism for over 50% of currently marketed medications \[[@CR159]\]. The clinical implications of M3's inhibition of CYP3A4 may be far reaching, as one of the phase IIb dercernotinib studies excluded not only subjects taking moderate or strong inhibitors or inducers of CYP3A4 and p-glycoprotein, but also subjects taking any medication metabolized via CYP3A4 with the potential for toxicity at high levels of exposure \[[@CR160]\]. In addition, adverse effects of this drug included elevations in lipid parameters \[[@CR80], [@CR132], [@CR160]\]. Notably, several high-potency, commonly used hydroxymethylglutaryl Co-A reductase inhibitors (statins) including simvastatin and atorvastatin are metabolized via CYP3A4 \[[@CR161]\]. Therefore, concomitant use with decernotinib could potentially increase the risk for statin-associated toxicity.

*Decernotinib in RA* Clinical data using decernotinib in RA have initially been promising. Phase II trials demonstrated efficacy at doses of 50--150 mg BID, with improvement of ACR response criteria and DAS28 joints using the CRP level (DAS28-CRP) compared with placebo. Adverse events reported were similar to first-generation Jakinibs such as infections, transaminitis, and hyperlipidemia \[[@CR126], [@CR160], [@CR162]\]. Anemia was not observed, consistent with selectivity for JAK3 over JAK2. Surprisingly, neutropenia was seen in a large number of patients, which may indicate that the drug could have some off-target effects \[[@CR157]\]. A phase IIb study recently demonstrated improvement in synovitis and osteitis with decernotinib along with conventional DMARDs in RA patients \[[@CR163]\].

### Filgotinib GLPG0634 {#Sec15}

Filgotinib inhibits both JAK1 and JAK2 in whole blood cell-based assays and kinase assays but displays an 30-fold selectivity towards JAK1 \[[@CR126]\]. In vitro studies also demonstrated a dose-dependent inhibition of Th1 and Th2 and, to lesser extent, Th17 cell differentiation.

*Metabolism and pharmacokinetics* In vitro analysis of the impact of filgotinib and its active metabolite on CYP enzymes indicate that neither agent inhibits nor induces CYP activity at clinically relevant concentrations \[[@CR164]\]. This conclusion was confirmed for CYP3A4 in a study on the impact of filgotinib on midazolam clearance in healthy volunteers, which showed no changes in midazolam metabolism \[[@CR164]\]. The potential of filgotinib to impact cell-based transport systems including p-glycoprotein and breast cancer resistance protein were examined in vitro, with the authors concluding that filgotinib was unlikely to inhibit these transport systems. The effects of filgotinib on organic cation transporters including organic cation transporter 2 were also examined in vitro with observed inhibition, but this is of unknown clinical significance. The potential for filgotinib to affect organic anion transporters implicated in methotrexate (MTX) clearance was explored, with no changes in MTX clearance observed in doses of filgotinib up to 300 mg \[[@CR164]\]. It appears that the unique pharmacokinetic profile of filgotinib may provide flexibility in dosing regimens (146).

*Filgotinib in autoimmune diseases* Filgotinib is currently is being investigated for the treatment of RA \[[@CR165]\]. Phase IIA studies in patients with active RA and inadequate response to MTX showed efficacy of filgotinib over placebo at doses of 30 mg daily and higher \[[@CR126], [@CR166]\]. This was followed by two phase IIb trials: DARWIN1 and DARWIN 2. DARWIN1 is a study on 595 MTX-treated RA patients where filgotinib was added at a range of doses from 50 mg daily to 100 mg BID. The DARWIN2 study assessed filgotinib monotherapy in 280 RA patients with doses ranging from 50 to 200 mg daily \[[@CR126]\]. In both studies, filgotinib was found to be superior to placebo in controlling disease activity as measured by ACR 20/50, DAS28-CRP, Simple Disease Activity Index (SDAI), and clinical disease activity index \[[@CR167], [@CR168]\].

Filgotinib is also being investigated in moderate to severe CD (FITZROY study) \[[@CR109], [@CR169]\]. Preliminary data from the trial showed significantly improved clinical outcomes and quality of life as measured by the clinical disease activity index and the inflammatory bowel disease questionnaire, respectively, with figlotinib compared with placebo \[[@CR170]\].

Safety profiles in both DARWIN trials and the FITZROY trial were all favorable. In the FITZROY study, filgotinib showed a favorable lipid profile with an increase in HDL and no change in LDL, resulting in an improved atherogenic index. An increase in hemoglobin was also observed and no clinically significant changes from baseline in neutrophils or liver function tests were observed, consistent with intact signaling through JAK2. Notably, a trial in patients with SLE was closed for lack of efficacy \[[@CR171]\].

### ABT494 {#Sec16}

ABT-494 is a next-generation Jakinib with 74-fold selectivity for JAK1 over JAK2, based on the drug's ability to bind JAK1 outside the adenosine triphosphate-binding site of JH1 in addition to the adenosine triphosphate binding site. Because the binding occurs with a less conserved domain, it is described as being specific for JAK1 \[[@CR172]\]. Importantly, as JAK2 and JAK3 signaling remain unaffected, ABT-494 does not affect erythropoietin signaling or reduce peripheral NK cell counts at therapeutic doses \[[@CR126]\].

Two multi-center, randomized, double-blind, placebo-controlled phase IIb studies (BALANCE I and II) were conducted in subjects with moderate to severe RA taking MTX who did not respond to either anti-TNF therapy (BALANCE I) or MTX (BALANCE II) (<http://www.clinicaltrials.gov> NCT01960855). Both studies demonstrated rapid improvement in ACR 20/50/70 and DAS28-CRP with ABT-494 compared with placebo. Improvements were observed as early as week 2 with ABT4-94 \[[@CR173], [@CR174]\]. Patient recruitment is currently ongoing for a phase III, double-blind, placebo-controlled study in RA with inadequate response to MTX, comparing ABT-494 with adalimumab on a stable background dose of MTX (<http://www.clinicaltrials.gov> NCT02629159).

### Peficitinib (ASP015K) {#Sec17}

Peficitinib (ASP015K) is a novel, orally bioavailable JAK inhibitor that inhibits JAK1, JAK2, JAK3, and TYK2 enzyme activities with moderate selectivity for JAK3 inhibition. Inhibition of JAK2 by peficitinib is relatively mild, which confers an acceptable safety profile \[[@CR175]\] and some potential advantages over first-generation inhibitors.

*Metabolism and pharmacokinetics* Similar to other Jakinibs, peficitinib exhibits rapid oral absorption. Interestingly, in metabolic studies, peficitinib possessed no single dominant clearance pathway \[[@CR176]\]. To date, clinically significant drug interactions with peficitinib have not been identified, and the major phase II trial with this agent lacked exclusion criteria based on potential drug interactions that may affect clearance of the Jakinib \[[@CR175]\].

*Peficitinib in autoimmune/inflammatory diseases* Peficitinib reduced paw swelling and ankle bone destruction in a preclinical model of rat adjuvant-induced arthritis \[[@CR177]\]. Early clinical studies have also been promising. A phase II trial in RA patients showed a statistically significant ACR 20 response compared with placebo at a range of doses from 25 to 150 mg \[[@CR175]\]. A phase IIa trial in plaque psoriasis demonstrated dose-dependent efficacy of peficitinib in PASI, body surface area (BSA), Physician Static Global Assessment, and histological measures of severity after 6 weeks \[[@CR178]\]. No major adverse events were reported by either of these trials.

### Solcitinib (GSK2586184) {#Sec18}

Solcitinib is another selective JAK1 inhibitor that has been evaluated for the treatment of moderate-to-severe plaque-type psoriasis. A 12-week, randomized, placebo-controlled clinical trial in moderate-to-severe plaque psoriasis revealed significant improvement in PASI 75 scores with solcitinib compared with placebo \[[@CR179]\].

Because JAK1 transmits signals downstream of type I IFNs, and patients with SLE have evidence of aberrant type I IFN signaling, solcitinib was therefore assessed in a phase II, randomized, placebo-controlled study of patients with moderate-to-severe SLE. However, two cases of drug reaction with eosinophilia and systemic symptoms syndrome and severe but reversible liver function test abnormalities in six subjects were reported, necessitating early termination of the study \[[@CR180], [@CR181]\]. What this means for the use of other Jakinibs in SLE remains unclear.

### INCB039110 {#Sec19}

INCB039110 is a next-generation JAK inhibitor with selective inhibitory action against JAK1. INCB-039110 was demonstrated as having a \>20-fold selectivity for JAK1 over JAK2 and a \>200-fold selectivity over JAK3. Preclinical studies supported its efficacy in mouse adjuvant arthritis models, at doses that did not inhibit the biological activity of erythropoietin. INCB039110 has also been shown to inhibit inflammatory pathways involved in the pathogenesis of psoriasis \[[@CR182], [@CR183]\].

A phase II, multi-center clinical trial using this drug to treat active RA demonstrated clinically significant improvement in ACR 20/50/70 and DAS28-CRP compared with placebo (<http://www.clinicaltrials.gov> NCT01626573) \[[@CR126], [@CR184]\], at doses ranging from 100 mg BID to 600 mg daily. A phase II clinical trial in plaque psoriasis was also encouraging, with improvement in PASI 50/75, PSGA, and affected body surface area in patients receiving INCB039110 compared with placebo \[[@CR182]\]. Common adverse effects were similar to those seen with nonselective Jakinibs and included infectious nasopharyngitis, elevated transaminases, and hypertriglyceridemia \[[@CR182]\].

Jakinibs in Preclinical Development {#Sec20}
-----------------------------------

Several biotechnology companies are in the process of developing JAK inhibitors with the goal of creating a molecule with maximum efficacy and minimum off target effects \[[@CR126]\]. The newer Jakinibs are isoform specific, which is postulated to diminish adverse events found with first generation non-selective Jakinibs. Some of the new-generation Jakinibs are covalently bound to specific sequences of the JAKs, resulting in better selectivity \[[@CR126]\]. Table [6](#Tab6){ref-type="table"} summarizes additional JAK inhibitors in various stages of clinical and preclinical development.Table 6Janus Kinase Inhibitors in preclinical and early clinical developmentDrugSpecificityClinical StatusDiseasesOP0155 \[[@CR199]\]JAK3PreclinicalRat adjuvant induced arthritisVR588 \[[@CR200]\]Pan JAK inhibitor (inhalational)PreclinicalAsthmaSHR0302 \[[@CR201]\]JAK1, JAK2, JAK3 (strongest binding to JAK1)Phase 1Rheumatoid arthritisPf-04965842 \[[@CR202]\]JAK1Phase 2b (ClinicalTrials.gov. NCT02780167)Moderate To Severe Atopic DermatitisJTE-052 \[[@CR203]\]JAK1, 2, 3 and Tyk2Phase 2 (in Japan)Atopic dermatitis, auoimmune disorders*JAK* Janus kinase

STAT Inhibition {#Sec21}
===============

As JAK substrates and key signaling molecules downstream of type I/II cytokine receptors, STATs have been investigated as an attractive target in the treatment of inflammation and autoimmunity, as well as malignancy. STAT3 is essential for signaling downstream of IL-6, which regulates the production of IL-17 by T cells and other immune cells, implicating STAT3 in the pathogenesis of many rheumatologic diseases \[[@CR185], [@CR186]\]. Moreover, constitutive activation of STAT3 and STAT5 has been observed in several human cancers and cancer cell lines \[[@CR50]\].

Blocking the action of transcription factors, however, is much more challenging than inhibiting the activity of enzymes such as kinases. Challenges to the development of STAT inhibitors include issues with bioavailability and selectivity. For example, considerable homology exists between STAT1 and STAT3. STAT1 facilitates vital functions including cell death, apoptosis, and pathogen defense, thus off-target STAT1 blockade by a STAT3 inhibitor can lead to a host of undesired adverse effects such as increased survival of tumor cells \[[@CR33], [@CR187], [@CR188]\]. Another challenge in developing STAT inhibitors is functional redundancy in the action of different STATs. Specifically, although STAT3 is critical for signaling downstream of IL-6, STAT3-deficient cells continue to respond to IL-6 stimulation through activation of STAT1 \[[@CR189]\]. Thus, selective blockade of one STAT molecule may not be clinically useful, as another STAT might compensate for the inhibited protein.

Despite these limitations, several small-molecule inhibitors targeting the SH2 domain have been developed and tested in phase I and II clinical trials. One of these, OPB-31121, was studied in a phase I/II trial for hepatocellular carcinoma but had an unacceptable adverse effect profile, particularly peripheral neuropathy, and limited efficacy \[[@CR190]\]. Another inhibitor, OPB-51602, appears safe and effective in the treatment of solid organ malignancies such as lung cancer \[[@CR57]\] but is also associated with a high risk of peripheral neuropathy and has poor bioavailability, further limiting its tolerability \[[@CR57], [@CR191]\]. STAT6 plays an important role in allergic pathways acting downstream to IL-4 and IL-13. Phosphopeptides blocking the SH2 domain of STAT6 are being developed to inhibit phosphorylation and further downstream signaling of this pathway, which may be useful in allergic diseases such as bronchial asthma \[[@CR192]\].

Because of difficulties with small-molecule inhibitors that target the SH2 domain, several other mechanisms of inhibition are being explored. STAT3 decoy oligonucleotides target the DNA-binding domain of the STAT and are much more selective than inhibitors that target the SH2 domain. However, phase 0 studies revealed that the first generation of decoys degraded quickly in vivo, limiting their effectiveness \[[@CR19]\]. Development of intrabodies against phosphorylated forms of the STAT3 molecule have been shown to be effective in in vitro studies \[[@CR193]\] and may represent another method of successfully targeting STATs therapeutically. Nonetheless, however promising STAT inhibition may be in the treatment of malignancy and autoimmunity, there are currently no clinical trials of STAT inhibitors actively recruiting patients.

Future Prospects for JAK--STAT Signaling Modulators in Inflammatory/Autoimmune Diseases {#Sec22}
=======================================================================================

Given the number of cytokines that signal through the JAK--STAT pathway, it is no surprise that Jakinibs have become the first kinase inhibitors used successfully in the treatment of rheumatologic disease. At present, tofacitinib is the only Jakinib approved for autoimmune disease, but several more may soon follow as new data emerge and the development of novel agents continues. Clinical trials are ongoing with various Jakinibs in several autoimmune conditions ranging from rheumatoid arthritis to psoriasis. Similarly, diseases characterized by serum elevations of JAK-dependent cytokines could respond well to Jakinibs. These include diseases for which a type I IFN signature has been defined such as SLE, myositis, scleroderma, and primary Sjogren's syndrome, as well as diseases driven by IL-6 such as relapsing polychondritis and large-vessel vasculitis. Several trials are indeed probing the efficacy of Jakinibs in the treatment of diseases characterized by an IFN signature, based on preclinical data \[[@CR194]\] and on the observation that baricitinib is effective for the treatment of monogenic interferonopathies such as chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome and SAVI \[stimulator of interferon genes (STING) associated vasculopathy with onset in infancy\], which are also associated with a type I IFN signature \[[@CR138]\]. Moreover, the preliminary success of Jakinibs in the treatment of alopecia and other skin-related diseases such as vitiligo is very exciting as no existing therapy has been effective in these relatively common conditions so far \[[@CR195]--[@CR197]\].

Optimal dosing strategies of Jakinibs also deserve further study, whereas currently approved regimens rely on a single dose for induction of remission and maintenance, it is not clear that this is the optimal strategy. It is possible that loading patients with high doses to induce remission, followed by a lower maintenance dose, would be a more effective strategy, as is the case for corticosteroids. Investigations of non-oral formulations of Jakinibs are also in the preliminary stages for diseases including psoriasis, allergic dermatitis, and ocular disease. Finally, biomarker development is ongoing to identify groups of patients with disease likely to respond to Jakinibs, as complex rheumatologic diseases may be driven by JAK-dependent cytokines to a different degree in different patients \[[@CR198]\]. After the era of biologics, the development of Jakinibs and their successful use in autoimmune and inflammatory diseases heralds an exciting new chapter in rheumatology. These drugs are unique both structurally and functionally, as small molecules that can be administered orally rather than injected, and which simultaneously block multiple cytokines downstream of their receptors. In the coming years, Jakinibs are poised to change the field of autoimmune and rheumatologic diseases as ongoing basic, preclinical, and clinical research will surely determine the feasibility and benefits of selectivity, optimized dosing, formulation, and patient selection to minimize undesirable off-target effects and maximize clinical efficacy.

An erratum to this article is available at <http://dx.doi.org/10.1007/s40265-017-0772-7>.

An erratum to this article is available at <http://dx.doi.org/10.1007/s40265-017-0736-y>.
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